Comparison of the Effect of Exenatide vs. Sitagliptin on 24-Hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

Trial Profile

Comparison of the Effect of Exenatide vs. Sitagliptin on 24-Hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2014

At a glance

  • Drugs Exenatide; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Amylin Pharmaceuticals
  • Most Recent Events

    • 20 Sep 2010 Results were presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.
    • 12 Feb 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top